Matinas BioPharma : Investor Presentation

Corporate Presentation

April/May 2021

1

Forward-Looking Statement

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K,10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

2

Company Highlights

LNC PLATFORM

Lipid Nanocrystal (LNC) Delivery

Technology

• Proprietary and potentially disruptive platform technology focused on improving intracellular delivery of critical therapeutics
• MAT2203 (oral amphotericin B): Cohort 2 update of EnACT study in cryptococcal meningitis expected Q3 2021. Enrollment >50% and on schedule.
• MAT2501 (oral amikacin): Recent $3.75M funding from CFF accelerates development of potential first oral aminoglycoside for treatment of nontuberculous mycobacterial disease and acute bacterial infections (i.e., gram negative)
• Collaborations: with NIH (oral formulation of Gilead's remdesivir),
  Genentech and others exploring LNC formulations of innovative compounds

3

LYPDISO™ (MAT9001)

Next Generation

Prescription Omega-3

• ENHANCE-ITdata reported in Q1 2021 demonstrated robust plasma EPA levels vs. Vascepa®, supporting pursuit of a cardiovascular outcomes indication
• Clear differentiation from currently approved prescription omega-3 products, supported by strong barriers to entry
• Process underway to identify a partner for further development and commercialization

3

Lipid Nanocrystal (LNC) Platform

Targeted, Well-Tolerated

Intracellular Delivery

4

The Current Landscape of Intracellular Drug Delivery

		Contents to be delivered		Target cells		Therapeutic areas		Delivery technology options
Small molecules:		Infected cells		Anti-inflammatory Rx		Liposome
	Antibiotic		Macrophages		Infectious disease		LNP
	Antifungal		Injured cells		Oncology		Viral vector
	Antiviral		Tumor cells		Vaccines	 LNC
	Anti-tumor
	Bone marrow cells		Gene therapy
	Anti-inflammatory		Monocytes
Gene therapy:		Dendritic cells
	Oligonucleotides
	DNA
	mRNA
	CRISPR/CAS-9

The future of

intracellular delivery

• Emerging importance of cell-mediated immunity (vaccines, immune enhancers)
• Growing needs for inhaled therapies (direct delivery to sites of infection)
• Need for more stable formulations ( AAV/LNP -80oC storage)
• Need for improved delivery efficiency (LNP 1-2% endosomal escape)
• Opportunities to improve safety profile of AAV and LNPs: toxicity and immunogenicity
• Formulations of larger molecules: mRNA-protein complexes

5